Fengzhi Li
Affiliations: | Roswell Park . Cellular and Molecular Biology | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Molecular Biology, OncologyGoogle:
"Fengzhi Li"Children
Sign in to add trainee| Pasha Apontes | grad student | 2011 | SUNY Buffalo |
| Andrew C. Haller | grad student | 2013 | SUNY Buffalo |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li F, Ling X, Chakraborty S, et al. (2023) Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence. Journal of Experimental & Clinical Cancer Research : Cr. 42: 213 |
| Ling X, Wu W, Liao J, et al. (2020) Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment. Journal of Clinical Oncology. 38: e16102-e16102 |
| Santha S, Aljahdali I, Rasam SS, et al. (2020) Role of mutant KRAS as a biomarker in FL118-induced apoptosis, reactive oxygen species (ROS) production and inhibition of survivin, Mcl-1 and XIAP in human bladder cancer. Journal of Clinical Oncology. 38: e15651-e15651 |
| Li F, Aljahdali I, Ling X. (2019) Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? Journal of Experimental & Clinical Cancer Research : Cr. 38: 368 |
| Rabi T, Li F. (2018) Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. American Journal of Cancer Research. 8: 2267-2283 |
| Ling X, Wu W, Fan C, et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. Journal of Experimental & Clinical Cancer Research : Cr. 37: 240 |
| Wolff DW, Lee MH, Jothi M, et al. (2018) Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells. Oncotarget. 9: 25796-25807 |
| Westover D, Li F. (2015) New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. Journal of Experimental & Clinical Cancer Research : Cr. 34: 159 |
| Westover D, Ling X, Lam H, et al. (2015) FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Molecular Cancer. 14: 92 |
| Ling X, Xu C, Fan C, et al. (2014) FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Research. 74: 7487-97 |